Trials / Unknown
UnknownNCT04928105
Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma
Clinical Study of Senl-T7 CAR-T Cells in the Treatment of Relapsed or Refractory CD7+ Lymphoma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd. · Industry
- Sex
- All
- Age
- 2 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open and prospective clinical study, taking patients with relapsed or refractory CD7+ lymphoma as the test subjects, in order to evaluate the safety and efficacy of Senl-T7 CAR-T for patients with CD7+ lymphoma.
Detailed description
Main research purposes: To evaluate the safety and efficacy of Senl-T7 CAR-T for relapsed or refractory CD7+ lymphoma Secondary research purpose: To investigate the cytokinetic characteristics of Senl-T7 CAR-T for relapsed or refractory CD7+ lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Senl-T7 | Patients will be treated with CD7 CAR-T cells |
Timeline
- Start date
- 2021-01-27
- Primary completion
- 2023-01-31
- Completion
- 2023-03-31
- First posted
- 2021-06-16
- Last updated
- 2022-05-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04928105. Inclusion in this directory is not an endorsement.